The NeurologyLive® movement disorders clinical focus page is a source for all the latest news regarding the clinical care of patients with Parkinson disease, essential tremor, Huntington disease, dystonia, ataxia, and more. This page features podcasts, videos, and news about FDA actions, study and clinical trial findings, clinical guideline updates, and interviews with experts in the clinical care of movement disorders.
August 25th 2025
Experts shared their clinical perspectives on trending topics in the treatment and management of movement disorders at the 4th Annual Advanced Therapeutics in Movement and Related Disorders (ATMRD) Congress.
Neurosteer Single-Channel EEG Platform Cleared by FDA
November 4th 2022The brain monitoring platform can be used in a number of settings, including the ICU and doctor’s offices, to monitor and detect cognitive decline related to neurodegenerative disease, as well as screening in clinical trials.
NeurologyLive® Brain Games: October 23, 2022
October 23rd 2022Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the European Committee for Treatment and Research in Multiple Sclerosis.
Deutetrabenazine Tablets Show Long-term Safety, Efficacy as Huntington Disease Chorea Treatment
October 21st 2022For patients who rolled over to the ARC-HD extension study from the previous First-HD trial, there was a 4.5-point reduction in mean chorea scores at week 8 that were maintained through week 145.
Phase 3 LIGHTHOUSE Study of LRRK2 Inhibitor BIIB122 Initiated in Parkinson Disease
October 12th 2022Similar to the recently commenced phase 2b LUMA study, BIIB122, an investigational small molecule inhibitor of LRRK2, will be evaluated in a cohort of 400 individuals with genetically mutated Parkinson disease.
Putting Pen to Paper: Executing on Approaches for Neurorestoration
October 11th 2022Joe Kardine, MS, OTR, CBIS, the clinical program manager at the Jefferson Center for Neurorestoration, discussed the influx of new neurorestorative technology and the future of treating patients with functional loss.
Supernus Issued CRL for Continuous Apomorphine Infusion in Parkinson Disease
October 10th 2022The NDA for the Supernus therapy, supported by data from the phase 3 TOLEDO study in patients with Parkinson disease, will require additional information and 6 months of further review. No additional efficacy or safety studies are required.
Combination of Biomarkers Associated with Stronger Predictions of Progression in Parkinson Disease
October 8th 2022Findings from a study on Parkinson disease revealed that combining blood biomarkers in addition with clinical measures with prognostics modelling are associated with a more vital prediction in disease progression.
Virtual Yoga Program Beneficial for Individuals With Functional Neurological Disorder
October 4th 2022Danielle Kipnis, MA, of Columbia University, discussed the practice of yoga for people with functional neurological disorders from her research and recommendations for future studies in the field.
NeurologyLive® Brain Games: October 2, 2022
October 2nd 2022Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is general neurology, related to the recent 4th Annual International Congress on the Future of Neurology®.